Abstract
Author(s): SubashiniRajaram*, P. Aruna,Jyotsna Ramesh, Liby MathewandD.Shanmughapriya
The present study aimed to formulate and evaluate pulsatile tablet of Ramipril and Telmisartan in capsule device using Eudragit RL100 and Eudragit RS100 polymers for the treatment of hypertension. The core tablet of telmisartan for sustained release was prepared by direct compression method. The blend of ramipril produced immediate release to the environment (acidic). The blend and core tablet were incorporated with hard gelatin capsulewith “1” in its size and the filled capsules were evaluated for its physico-chemical characteristics. The pre, post compression evaluation result complies with the standard limits with minimum standard deviations. The in-vitro drug release profile of immediate release layer shows that formulation FM3results 60% drug release at 20 min and it was achieved to 98% at 50 min. The in-vitro release study of core tablet such as telmisartan start its release at 3rdhour and 98% of drug release was achieved by FS3at 12thhour and it was linear compare to other formulations prepared. In conclusion, pulsatile drug delivery could be beneficial to deliver the drug at right time and right environment for hypertensive therapy and also it improves the patient’s compliance